Profile

FU-SHENG WU,Doctoral supervisor, Chief Physician, Deputy Director of the Department of Surgical Oncology,Vice Chairman of Cancer Biotherapy Committee of Zhejiang Anti-Cancer Association, mainly engaged in surgical treatment on liver, gastric, breast, thyroid and soft tissue tumors, and is especially adept at treatment on gastric and thyroid tumors. Currently working on metastasis and recurrence of liver cancer, the subject-“block cellular signal transduction pathways prevent recurrence and metastasis of liver cancer”won the Zhejiang provincial health technology innovation first prize in 2008.
On-going Project: National High-tech and Program (National 863 Program): Explorary study on the potential function and anti-cancer effect of tumor-associated microRNA.
As the first author or corresponding author,WU have published more than 10 papers,including 3 SCI papers,in the core journals at home and abroad.

Publications
1. Role of specific microRNAs for endothelial function and angiogenesis. Biochem Biophys Res Commun. 2009 ;386(4):549-53.
2. Calcitriol inhibits the growth of MHCC97 heptocellular cell lines by down-modulating c-met and ERK expressions. Liver International, 2007.27(5):700-707
3. The clinical value of hepatocyte growth factor and its receptor-c-met for liver cancer patients with hepatectomy. Dig Liver Dis. 2006,38(7): 490-497
4. Calcitriol combined with lipiodol ultra-fluid inhibits the growth of MHCC97 hepatocellular carcinoma cell lines. Chin J Gen Surg, 2007,22(11):801～804
5. Influence of age and gender on the pharmacokinetics of propofol in neurosurgical patients: model development. Acta Pharmacologica Sinica, 2006; 27(5): 629-634.
6. Prognostic factors influencing postoperative survival in patients with 7. The Chinese classification system compared with TNM staging in prognosis of patients with primary hepatic carcinoma after resection. Hepatobiliary Pancreat Dis Int. 2005;4(4):561-564.
8. Malignant gastric carcinoids with liver metastases, Hepatobiliary Pancreat Dis Int, 2004,3（3）:406-410